首页 > 文章详情

【2016 SABCS】PL2 乳腺肿瘤学中的无细胞血浆肿瘤DNA

2016年12月08日

编译：mackaay

来源：肿瘤资讯

[PL2] PL2 Cell free plasma tumor DNA in breast oncology - 09:00 AM

Park BH The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

In the past decade, there has been great interest in the use of circulating cell-free DNA to help guide therapy decisions in clinical oncology. Recent work by our group and others suggests that circulating cell-free plasma tumor DNA offers advantages compared to tissue biopsies for mutation profiling. This concept of “liquid biopsy” may allow for a more global genomic picture of metastatic disease since blood serves as a reservoir for all metastatic sites. In addition, cell-free plasma tumor DNA can be measured serially and quantitatively, presenting the possibility of using circulating plasma tumor DNA as a biomarker to measure disease burden and response to therapies for both early and late stage disease. In this session, I will review historic and recent studies demonstrating the clinical potential of measuring cell-free plasma tumor DNA in breast cancer patients for early stage and metastatic disease. I will also outline future steps needed to translate liquid biopsies from research use to clinical practice, and recent work highlighting the first multi-institutional prospective clinical trial evaluating cell-free plasma tumor DNA in early stage breast cancer patients undergoing neoadjuvant chemotherapy.

乳腺肿瘤学中的无细胞血浆肿瘤DNA

在过去的十年中，对使用循环游离DNA有助于指导临床肿瘤学中的治疗决定已经引起广泛的兴趣。我们小组和其他人最近的工作表明，与用于突变谱的组织活检相比，循环的无细胞血浆肿瘤DNA提供了许多优势。“液体活检”的这种概念可以允许对转移性疾病进行更全面的基因组深入了解，因为血液用作所有转移部位的储藏库。此外，可以连续和定量测量无细胞血浆肿瘤DNA，实现使用循环血浆肿瘤DNA作为生物标志物来测量疾病负荷、监测对早期和晚期疾病的治疗反应的可能性。在本次会议中，我将回顾历史和最近的研究，证明在乳腺癌患者的早期和转移性疾病中测量无细胞血浆肿瘤DNA的临床潜力。我还将概述将液体活检从研究用途转移到临床实践所需的未来步骤，以及一项最新的工作，分析了在进行新辅助化疗的早期乳腺癌患者中评价无细胞血浆肿瘤DNA的第一个多机构前瞻性的临床试验。

WechatIMG144副本.jpg

与全世界的肿瘤医生一起交流→

查看详情